Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.
The US Food and Drug Administration (FDA) has announced increased flexibility for cell and gene therapy (CGT) manufacturers, loosening quality requirements in an effort to expedite patient access.
